Ex Vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 961-966

  Marfurt, Jutta ^a   Chalfein, Ferryanto ^b   Prayoga, Pak ^b   Wabiser, Frans ^b   Kenangalem, Enny ^b,c   Piera, Kim A ^a   Fairlie, David P ^d   Tjitra, Emiliana ^e   Anstey, Nicholas M ^a   Andrews, Kathy T ^f   Price, Ric N ^a,g  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c District Ministry of Health   (Indonesia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^f QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOSUBERIC ACID 14; 2 AMINOSUBERIC ACID 9; ARTESUNATE; CHLOROQUINE; HISTONE DEACETYLASE INHIBITOR; MEFLOQUINE; PIPERAQUINE; UNCLASSIFIED DRUG; VORINOSTAT; WR 308364;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; EX VIVO STUDY; GROWTH INHIBITION; IC 50; INDONESIA; MICROBIAL GROWTH; MICROBIAL SENSITIVITY TEST; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PAPUA NEW GUINEA; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL; SCHIZONT; SPECIES DIFFERENCE;

DRUG RESISTANCE, MULTIPLE, BACTERIAL; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; MICROBIAL SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX;

EID: 79952341758     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01220-10     Document Type: Article

References (50)

1. Akoachere, M., et al. 2005. In vitro assessment of methylene blue on chloroquine-sensitive and -resistant Plasmodium falciparum strains reveals synergistic action with artemisinins. Antimicrob. Agents Chemother. 49:4592-4597.
2. Andrews, K. T., et al. 2008. Potent antimalarial activity of histone deacetylase inhibitor analogues. Antimicrob. Agents Chemother. 52:1454-1461.
3. Andrews, K. T., T. N. Tran, N. C. Wheatley, and D. P. Fairlie. 2009. Targeting histone deacetylase inhibitors for anti-malarial therapy. Curr. Top. Med. Chem. 9:292-308.
4. Andrews, K. T., et al. 2000. Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents. Int. J. Parasitol. 30:761-768.
5. Barcus, M. J., et al. 2007. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Am. J. Trop. Med. Hyg. 77:984-991.
6. Cang, S., Y. Ma, and D. Liu. 2009. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J. Hematol. Oncol. 2:22.
7. Chaal, B. K., A. P. Gupta, B. D. Wastuwidyaningtyas, Y. H. Luah, and Z. Bozdech. 2010. Histone deacetylases play a major role in the transcriptional regulation of the Plasmodium falciparum life cycle. PLoS Pathog. 6:e1000737.
8. Daher, W., et al. 2006. In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab. Dispos. 34:667-682.
9. Dar, O., M. S. Khan, and I. Adagu. 2008. The potential use of methotrexate in the treatment of falciparum malaria: in vitro assays against sensitive and multidrug-resistant falciparum strains. Jpn. J. Infect. Dis. 61:210-211.
10. de Pilla Varotti, F., et al. 2008. Synthesis, antimalarial activity, and intracellular targets of MEFAS, a new hybrid compound derived from mefloquine and artesunate. Antimicrob. Agents Chemother. 52:3868-3874.
11. Douglas, N. M., N. M. Anstey, B. J. Angus, F. Nosten, and R. N. Price. 2010. Artemisinin combination therapy for vivax malaria. Lancet Infect. Dis. 10:405-416.
12. Dow, G. S., et al. 2008. Antimalarial activity of phenylthiazolyl-bearing hydroxamate- based histone deacetylase inhibitors. Antimicrob. Agents Chemother. 52:3467-3477.
13. Duraisingh, M. T., and P. Refour. 2005. Multiple drug resistance genes in malaria-from epistasis to epidemiology. Mol. Microbiol. 57:874-877.
14. Duraisingh, M. T., et al. 2005. Heterochromatin silencing and locus repositioning linked to regulation of virulence genes in Plasmodium falciparum. Cell 121:13-24.
15. Fedier, A., K. J. Dedes, P. Imesch, A. O. Von Bueren, and D. Fink. 2007. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Int. J. Oncol. 31:633-641.
16. Freitas-Junior, L. H., et al. 2005. Telomeric heterochromatin propagation and histone acetylation control mutually exclusive expression of antigenic variation genes in malaria parasites. Cell 121:25-36.
17. Genton, B., et al. 2008. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med. 5:e127.
18. Grant, S., C. Easley, and P. Kirkpatrick. 2007. Vorinostat. Nat. Rev. Drug Discov. 6:21-22.
19. Guglielmo, S., et al. 2009. A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity. Eur. J. Med. Chem. 44:5071-5079.
20. Hauswald, S., et al. 2009. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin. Cancer Res. 15:3705-3715.
21. Hay, S. I., C. A. Guerra, A. J. Tatem, A. M. Noor, and R. W. Snow. 2004. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect. Dis. 4:327-336.
22. Hu, G., et al. 2010. Transcriptional profiling of growth perturbations of the human malaria parasite Plasmodium falciparum. Nat. Biotechnol. 28:91-98.
23. Joshi, M. B., et al. 1999. Molecular cloning and nuclear localization of a histone deacetylase homologue in Plasmodium falciparum. Mol. Biochem. Parasitol. 99:11-19.
24. Kahnberg, P., et al. 2006. Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid. J. Med. Chem. 49:7611-7622.
25. Karyana, M., et al. 2008. Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar. J. 7:148.
26. Kelly, W. K., et al. 2005. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23:3923-3931.
27. Kelly, W. K., et al. 2003. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9:3578-3588.
28. Kim, Y. K., et al. 2008. Histone deacetylase inhibitor apicidin-mediated drug resistance: involvement of P-glycoprotein. Biochem. Biophys. Res. Commun. 368:959-964.
29. Kocken, C. H., et al. 2006. Plasmodium vivax: in vitro susceptibility of blood stages to synthetic trioxolane compounds and the diamidine DB75. Exp. Parasitol. 113:197-200.
30. Muangnoicharoen, S., D. J. Johnson, S. Looareesuwan, S. Krudsood, and S. A. Ward. 2009. Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro. Antimicrob. Agents Chemother. 53:1362-1366.
31. Nomura, T., et al. 2001. Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria. J. Infect. Dis. 183:1653-1661.
32. Patel, V., et al. 2009. Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum. J. Med. Chem. 52:2185-2187.
33. Patil, V., et al. 2010. Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group. Bioorg. Med. Chem. 18:415-425.
34. Price, R. N., et al. 1999. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob. Agents Chemother. 43:2943-2949.
35. Price, R. N., N. M. Douglas, and N. M. Anstey. 2009. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr. Opin. Infect. Dis. 22:430-435.
36. Ratcliff, A., et al. 2007. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans. R. Soc. Trop. Med. Hyg. 101:351-359.
37. Richards, W. H., and S. G. Williams. 1973. The removal of leucocytes from malaria infected blood. Ann. Trop. Med. Parasitol. 67:249-250.
38. Russell, B., et al. 2008. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob. Agents Chemother. 52:1040-1045.
39. Russell, B. M., et al. 2003. Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic. Antimicrob. Agents Chemother. 47:170-173.
40. Sharrock, W. W., et al. 2008. Plasmodium vivax trophozoites insensitive to chloroquine. Malar. J. 7:94.
41. Sumawinata, I. W., et al. 2003. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am. J. Trop. Med. Hyg. 68:416-420.
42. Suwanarusk, R., et al. 2008. Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax. J. Infect. Dis. 198:1558-1564.
43. Suwanarusk, R., et al. 2007. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS One 2:e1089.
44. Tan, J., S. Cang, Y. Ma, R. L. Petrillo, and D. Liu. 2010. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 3:5.
45. Tjitra, E., et al. 2008. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 5:e128.
46. Wernsdorfer, W. H., and I. McGregor. 1989. Malaria: principles and practice of malariology. Churchill Livingstone, Edinburgh, Scotland, United Kingdom.
47. World Health Organization. 2008. World malaria report 2008. World Health Organization publication no. WHO/HTM/GMP/2008.1. World Health Organization, Geneva, Switzerland.
48. Xiao, J. J., et al. 2005. Chemoresistance to depsipeptide FK228 [(E)- (1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia- 5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J. Pharmacol. Exp. Ther. 314:467-475.
49. Xu, W. S., R. B. Parmigiani, and P. A. Marks. 2007. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26:5541-5552.
50. Yang, X. J., and E. Seto. 2007. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26:5310-5318. (Pubitemid 47255917)